Goldman Sachs analyst Richard Law initiated coverage of Crinetics (CRNX) with a Neutral rating and $36 price target The sees the stock’s near-term value being meaningfully influenced by uncertainties of paltusotine’s and Crenessity’s launch performances given Crinetics’ lack of other meaningful pipeline catalysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
- Crinetics Pharmaceuticals Presents at ENDO 2025 Meeting
- 3 Best Stocks to Buy Now, 6/30/2025, According to Top Analysts
- Crinetics Pharmaceuticals: Promising Pipeline and Strategic Focus Drive Buy Rating
- Crinetics Pharmaceuticals: Strategic Focus on Early-Stage Pipeline and Long-Term Value Creation Drives Buy Rating